id: NEW:metabolic_dysfunction_associated_fatty_liver_disease_mafld_to_NEW:hepatocellular_carcinoma_incidence
name: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) â†’ Hepatocellular
  Carcinoma Incidence
from_node:
  node_id: NEW:metabolic_dysfunction_associated_fatty_liver_disease_mafld
  node_name: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
to_node:
  node_id: NEW:hepatocellular_carcinoma_incidence
  node_name: Hepatocellular Carcinoma Incidence
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: MAFLD develops through metabolic dysfunction characterized by hepatic steatosis
  combined with markers of metabolic dysfunction (obesity, type 2 diabetes, or metabolic
  dysregulation)'
- 'Step 2: Chronic hepatic inflammation and oxidative stress from lipid accumulation
  leads to progressive liver damage, promoting hepatocyte injury and regeneration
  cycles'
- 'Step 3: Sustained metabolic stress and inflammation drive fibrosis progression,
  which can advance to cirrhosis in many cases'
- 'Step 4: The pro-oncogenic microenvironment created by chronic inflammation, insulin
  resistance, and lipotoxicity promotes hepatocellular transformation and carcinogenesis'
- 'Step 5: MAFLD contributes to HCC both as a sole etiology (single-MAFLD) and as
  a co-factor potentiating other liver diseases (mixed-MAFLD), with nearly half of
  all HCC cases having MAFLD involvement'
evidence:
  quality_rating: A
  n_studies: 22
  primary_citation: 'Harry Crane et al. 2024. Global prevalence of metabolic dysfunction-associated
    fatty liver disease-related hepatocellular carcinoma: A systematic review and
    meta-analysis. Clinical and Molecular Hepatology.'
  supporting_citations: []
description: MAFLD is a major contributor to hepatocellular carcinoma, with nearly
  half (48.7%) of all HCC cases having MAFLD involvement. MAFLD can act as the sole
  cause of HCC (12.4% of cases) or more commonly as a contributory co-factor in mixed-etiology
  HCC. The metabolic dysfunction underlying MAFLD creates a pro-carcinogenic hepatic
  environment through chronic inflammation, lipotoxicity, and often cirrhosis development.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 48.7
    type: prevalence_percentage
    ci_lower: 34.5
    ci_upper: 63.0
  p_value: null
  sample_size: 56565
moderators:
- name: concurrent_liver_disease
  direction: strengthens
  strength: strong
  description: 'MAFLD prevalence is higher in mixed-etiology HCC: 40.0% with hepatitis
    B, 54.1% with hepatitis C, and 64.3% with alcohol-related liver disease'
- name: cirrhosis_status
  direction: strengthens
  strength: moderate
  description: Mixed-MAFLD HCC had significantly higher likelihood of cirrhosis compared
    to single-MAFLD HCC
